Home › Compare › CLRYF vs MRK

CLRYF vs MRK: Dividend Comparison 2026

CLRYF yields 2000000.00% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLRYF wins by $4.879226400974806e+39M in total portfolio value
10 years
CLRYF
CLRYF
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full CLRYF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — CLRYF vs MRK

📍 CLRYF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLRYFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLRYF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CLRYF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLRYF
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, CLRYF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLRYF + MRK for your $10,000?

CLRYF: 50%MRK: 50%
100% MRK50/50100% CLRYF
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CLRYF
No analyst data
Altman Z
-26.5
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLRYF buys
0
MRK buys
0
No recent congressional trades found for CLRYF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLRYFMRK
Forward yield2000000.00% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$4.879226400974806e+39M$30.7K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$950.29
Total dividends collected$4.879195005460081e+39M$6.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CLRYF vs MRK ($10,000, DRIP)

YearCLRYF PortfolioCLRYF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,192$351.54+$200.00M → CLRYF
2$3,738,731,768,458$3,738,517,757,009.35$12,524$392.70+$3738731.76M → CLRYF
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,015$438.65+$65315062866.92M → CLRYF
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$15,682$489.96+$1066400830062625.00M → CLRYF
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$17,547$547.23+$16272182796453826560.00M → CLRYF
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$19,632$611.16+$2.3205424011366188e+23M → CLRYF
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$21,963$682.53+$3.0927990661046884e+27M → CLRYF
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$24,571$762.18+$3.8524105697352695e+31M → CLRYF
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$27,486$851.08+$4.484688260147987e+35M → CLRYF
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$30,745$950.29+$4.879226400974806e+39M → CLRYF

CLRYF vs MRK: Complete Analysis 2026

CLRYF — Stock

Clarocity Corporation designs and develops real estate valuation and report products. The company develops software for residential housing appraisal research in the metropolitan areas throughout the United States, as well as a suite of realtor powered valuation products. It also provides alternative valuation and appraisal fulfillment services. The company was formerly known as Zaio Corporation and changed its name to Clarocity Corporation in October 2016. Clarocity Corporation is headquartered in Carlsbad, California.

Full CLRYF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this CLRYF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLRYF vs SCHDCLRYF vs JEPICLRYF vs OCLRYF vs KOCLRYF vs MAINCLRYF vs JNJCLRYF vs ABBVCLRYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.